Plain-English translation of NCT07259512 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication that helps protect your kidneys and heart, to find out whether it works better when you take it once a day or split it into two daily doses. You have both chronic kidney disease and heart failure, which means your kidneys and heart need extra support. The study will measure how well your kidneys respond to each dosing schedule over 30 days.
Right now, doctors aren't sure which way to give this medication works best for patients like you who have both kidney disease and heart failure. This trial will provide clear evidence about which dosing schedule helps protect your kidneys better.
You likely qualify if…
You likely don't qualify if…
You will take the medication every day for 30 days. Half of the participants will take one 10 mg dose once daily, while the other half will take 5 mg twice daily (morning and evening). During the study, you'll have blood tests to measure how your kidneys are responding and whether the medication is working as expected. The study is double-blind, meaning neither you nor the researchers will know which dosing schedule you're on until the study ends.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Indonesia